Biotechnology Gilead’s Aggressive Push Beyond HIV Treatments – Plans To Increase Cancer-Focused CAR-T Treatment Production – Gilead Sciences (NASDAQ:GILD) Read more
Stockmarkets Oppenheimer remain bullish on Gilead Sciences , HIV agents in 24/25 could provide conviction to investors By biedexmarkets.com Read more
Biotechnology Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead’s and Merck’s Combo Therapy – Merck & Co (NYSE:MRK), Gilead Sciences (NASDAQ:GILD) Read more
Biotechnology Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data Shows – GSK (NYSE:GSK), Pfizer (NYSE:PFE) Read more
Biotechnology Pfizer/GSK-Backed ViiV Healthcare’s HIV Drug Associated With Increased Resistance, WHO Report Says – GSK (NYSE:GSK), Pfizer (NYSE:PFE) Read more